The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been rapidly evolving. In the past, the use of chemotherapy was reserved for metastatic prostate cancer patients who developed castration resistance. Subsequently, there were three well-designed randomized controlled trials investigating the use of chemotherapy together with androgen deprivation therapy as the first-line treatment for metastatic hormone-sensitive prostate cancer. The GETUG-AFU 15 study was a negative trial, but the subsequent CHAARTED and STAMPEDE studies demonstrated magnificent survival benefit in the mHSPC setting. Since then, the use of chemohormonal therapy has become accepted and popularized worldwide. However, these results were largely based on Caucasians. Because of the genetic and physiological differences between different ethnicities, there has been concern over whether these results could be readily translated to the Asian population. Would Asians in general have a different tolerability towards chemohormonal therapy? Would prostate cancer in the Asian population have a different biological response towards chemohormonal therapy? In this review paper, we will present the available data regarding the use of chemohormonal therapy for mHSPC and discuss their implications from an Asian perspective.
INTRODUCTION
Prostate cancer is the second commonest malignancy in the male population. 1 In Hong Kong, the incidence of prostate cancer was 54. 4 per 100,000 persons, and more than 1800 new cases of prostate cancer were diagnosed in 2015. 2 We also observed a rapidly increasing life expectancy from 67.8 years in 1971 to 81.3 years in 2016 in our locality. 3 With an ageing population, we would have an increasing number of patients with prostate cancer in the future. With a longer followup period, we would also encounter more patients who develop disease progression despite initial treatment. Prostate cancer is a common and important disease, which continues to carry a significant burden to our healthcare system. Androgen deprivation therapy (ADT) was first introduced by Huggins et al. in 1941, 4 and it has been shown to lead to dramatic biochemical responses in patients with advanced prostate cancer. Although the use of ADT was associated with various adverse events, [5] [6] [7] [8] [9] [10] it has nevertheless become the cornerstone treatment for metastatic prostate cancer. In the past, the use of chemotherapy was reserved for patients who developed castration resistance. However, the survival benefit of chemotherapy in patients with metastatic castrationresistant prostate cancer is only modest. 11, 12 A number of clinical trials had been conducted to investigate the use of upfront chemotherapy together with ADT for patients with metastatic hormone-sensitive prostate cancer (mHSPC). [13] [14] [15] [16] This has led to landmark changes in the management of mHSPC, and the use of chemohormonal therapy has been accepted worldwide. However, there has been constant concern about whether the results of the clinical trials could be readily translated to the Asian population. Because of the genetic and physiological differences between different ethnicities, would the Asian population have a different tolerability towards chemohormonal therapy? Would prostate cancer in the Asian population have a different response towards chemohormonal therapy? In this paper, we shall review the available data and discuss these aspects from an Asian perspective. of 385 patients with mHSPC were randomized to receive ADT plus docetaxel or ADT alone. The median survival was 58.9 months in the ADT plus docetaxel group and 54.2 months in the ADT alone group, and there was no statistical difference between the two groups (HR = 1.01; 95% CI, 0.75-1.36, P = 0.955). The authors concluded that docetaxel should not be used as part of the first-line treatment for patients with mHSPC. The CHAARTED study is the first study demonstrating the benefit of chemohormonal therapy in patients with mHSPC. 13, 14 In this multicenter RCT, a total of 790 patients with mHSPC were randomized to receive ADT plus docetaxel or ADT alone. Patients in the ADT plus docetaxel group had a longer overall survival than the ADT alone group (median of 57.6 months vs 47.2 months). Patients were further stratified into having high-volume and low-volume disease, in which highvolume disease was defined as the presence of visceral metastases or ≥4 bone lesions with ≥1 beyond the vertebral bodies and pelvis.
For patients with high-volume disease, the median overall survival was 51.2 months in the ADT plus docetaxel group and 34.4 months in the ADT alone group (HR = 0.63; 95% CI, 0.50-0.79, P < 0.001).
However, for patients with low-volume disease, there was no overall survival difference between the two groups (HR = 1.04; 95% CI, 0.70-1.55; P = 0.86). The authors concluded that chemohormonal therapy could prolong overall survival in patients with high-volume disease, but not in those with low-volume disease. Subsequently, the STAM-PEDE study also demonstrated the benefit of chemohormonal therapy in patients with mHSPC. 15 The STAMPEDE study is a multiarm, multistage, and multicenter RCT, in four groups of prostate cancer patients. 
DIFFERENCES BETWEEN THE THREE RANDOMIZED CONTROLLED TRIALS
Among the three RCTs, two demonstrated the benefit of chemohormonal therapy and one did not. Are there any reasons that could explain the differences in the results? In order to understand this, we must look into the patients' and disease characteristics of the three RCTs (Table 1) . Among the three studies, the median baseline PSA level in the ADT plus docetaxel group was the lowest in the GETUG-AFU 15 study (GETUG-AFU 15: 26.7 ng/mL, CHAARTED: 50.9 ng/mL, STAM-PEDE: 70 ng/mL). Patients in the GETUG-AFU 15 also had the lowest proportion of patients having high Gleason scores of ≥8 (GETUG-AFU 15: 55%, CHAARTED: 60.7%, STAMPEDE: 74%). The proportion of patients having high-volume disease was not reported in the STAM-PEDE study. However, fewer patients in the GETUG-AFU 15 study had high-volume disease when compared to the CHAARTED study (48% vs 66%). Generally speaking, the patients in the GETUG-AFU 15 appear to have less advanced and lower risk diseases when compared to the CHAARTED and STAMPEDE studies. This could potentially marginalize the benefit of chemohormonal therapy and therefore lead to negative results. This highlights the impact of the differences in case mix, and it is extremely important to select the correct patients to receive the intended intervention. It is also important to have real-world data to evaluate whether the benefit of chemohormonal therapy could be readily translated in our clinical practice.
WHAT ARE THE MA JOR CONSIDERATIONS IN THE ASIAN POPULATION?
A collaborative report showed that prostate cancer patients in Asia tend to present at a later disease stage than those in the Western countries. 17 In China, for example, more than 20% of the prostate cancer patients present with metastatic disease. 17 Following the encouraging results from the CHAARTED and STAMPEDE studies, we should expect a huge impact in the management of mHSPC in our clinical practice. However, due to the genetic and physiological differ- The majority of the patients (93.7%) were also able to complete at least six cycles of chemotherapy. Among them, 40.6% developed grade 3 to 4 neutropenia and 12.5% developed febrile neutropenia, and this is comparable to our previous experience in metastatic castration resistant prostate cancer. 19 One patient had dose reduction, seven patients had delayed chemotherapy schedule, and one patient had discontinuation of chemotherapy because of treatment-related toxicities. Although the rates of hematologic toxicities appear to be higher than that in the Caucasian population (Table 2) , all treatment-related adverse events were adequately treated and there was no treatment-related mortality.
Careful patient selection is crucial, and preemptive use of granulocytecolony stimulating factor could be considered to minimize the risk of hematologic toxicities.
Using the above case series, a further age-and PSA-matched retrospective cohort study comparing between chemohormonal and hormonal therapy in patients with mHSPC is currently underway (unpublished data). We were able to match the cohorts with Although the clinical data regarding overall survival is still immature, we believe the benefit in PSA progression-free survival and castration resistance-free survival are encouraging, and the long-term outcome regarding overall survival is eagerly awaited.
TA B L E 1 Comparison of the randomized controlled trials investigating the use of chemohormonal therapy in prostate cancer

WHAT IS THE NEXT STEP FORWARD?
The use of chemohormonal therapy has led landmark changes in the management of mHSPC worldwide. However, given the paucity of literature, the utility of chemohormonal therapy in the mHSPC settings appears to be underutilized in the Asian population. There are two main reasons for the under-utilization of chemohormonal therapy.
First, the Asian population may not be as willing to accept chemotherapy due to the presumed toxicities. Patient education and counseling are essential to let our patients fully understand the pros and cons of chemohormonal therapy. Second, doctors in Asia may not be as willing to offer chemotherapy as part of the first-line treatment of mHSPC.
This could be due to the presumption that the data from the available RCTs might not be readily applicable in the Asian population in terms of both efficacy and tolerability. Nevertheless, our experience regarding the efficacy of chemohormonal therapy in Hong Kong is promising.
We should be aware of the toxicities of chemohormonal therapy, which could usually be managed adequately without major consequences.
Following our preliminary results, we expect an increasing acceptance and utility of chemohormonal therapy for mHSPC in our locality. More clinical data would be valuable to provide us more insights regarding the long-term efficacy of chemohormonal therapy for mHSPC in the Asian population.
The addition of abiraterone acetate, an androgen synthesis inhibitor, to conventional ADT is another approach that we can consider in patients with mHSPC. Two RCTs, namely the STAMPEDE and the LATITUDE studies, have demonstrated the survival benefit of abiraterone acetate in patients with mHSPC. 20, 21 Detailed description of the use of ADT plus abiraterone acetate is beyond the context of this paper. Nevertheless, the addition of abiraterone acetate is in general a very viable option for patients with mHSPC, which however could be limited by its high cost and reimbursement limitations.
CONCLUSION
The use of chemohormonal therapy should always be considered in patients with mHSPC. We observed a gradual change in treatment paradigm from ADT alone to chemohormonal therapy for mHSPC in Hong Kong. The initial concern about the toxicities of chemotherapy has become more acceptable to urologists and oncologists. Our preliminary results on the efficacy of chemohormonal therapy are promising. More clinical data on the long-term survival outcomes are eagerly awaited.
